Soligenix reports Q1 EPS (9c), consensus (13c)
Reports Q1 revenue $1.1M, consensus $1.15M. As of March 31 the Company's cash position was approximately $7.2M. The company stated "We have completed the approximate 90 subject enrollment necessary to support the interim efficacy analysis of our pivotal double-blind, placebo-controlled Phase 3 clinical trial of SGX942, or dusquetide, for the treatment of oral mucositis in patients with head and neck cancer receiving chemoradiation therapy. This interim analysis, to be conducted by the independent Data Monitoring Committee for the trial, is anticipated to occur in September 2019. We expect completion of full enrollment in the study in the second half of 2019, with final top-line results expected in the first half of 2020, pending the DMC recommendation. Following the positive recommendation received from the independent DMC for our double-blind, placebo-controlled Phase 3 study for the treatment of cutaneous T-cell lymphoma with SGX301 we continue to enroll patients and anticipate completing study enrollment in the second half of 2019, with final top-line results in the Q1 of 2020."